Category Archives: Press Releases

Firalis S.A. and Celemics Inc. launch the FiMICS® panel.

Firalis S.A. and Celemics, Inc. announce an agreement for the commercialization of a unique proprietary long non-coding RNA (lncRNA) panel, FiMICS®.  The precise quantification of 3233 cardiac-enriched lncRNAs in peripheral blood samples would better characterize patients with diverse cardiac disorders and toxicities. France, Huningue, 19th, September 2018 Firalis S.A. (“Firalis”), a Huningue based developer and…
Read more

FIRALIS S.A. announces the launch of the Biopred panel

FIRALIS S.A. announces the launch of the Biopred panel, an innovative RUO product that profiles thousands of mRNAs associated with inflammatory autoimmune disorders via a pioneering targeted mRNA profiling technology without RNA extraction. France, Huningue, 23th May 2018 Firalis S.A (“Firalis”), a developer of biomarker-based products and provider of biomarker services announced the release of…
Read more

Firalis S.A. has launched the EU-funded (EUROSTAR) HeartLinc Program

On 24th of March 2017, the EU-funded (EUROSTAR) HeartLinc program has been launched in Seoul, South Korea, during a first meeting between the Seoul National University Hospital (SNUH), the QuantaMatrix company (Seoul, South Korea) and the Firalis Group (Huningue, France). On 17th of June, the collaboration kicked off together with the European partners of the…
Read more

« Les Echos » article about Firalis collaboration on Rheumatoid Arthritis

« Les Echos », a prestigious financial journal, published an article on our collaboration with HTG Molecular Diagnostics about the development of a theranostic tool to predict response to anti‑TNFα therapies for Rheumatoid Arthritis (RA). Published on September 12th 2016. Click on the link below to view the related press news: « Firalis prédit l'efficacité des thérapies contre…
Read more